MX2010007406A - Anticuerpos anti-factor inhibidor de migracion de macrofago (mif). - Google Patents

Anticuerpos anti-factor inhibidor de migracion de macrofago (mif).

Info

Publication number
MX2010007406A
MX2010007406A MX2010007406A MX2010007406A MX2010007406A MX 2010007406 A MX2010007406 A MX 2010007406A MX 2010007406 A MX2010007406 A MX 2010007406A MX 2010007406 A MX2010007406 A MX 2010007406A MX 2010007406 A MX2010007406 A MX 2010007406A
Authority
MX
Mexico
Prior art keywords
antibodies
mif
relates
antigen
present application
Prior art date
Application number
MX2010007406A
Other languages
English (en)
Inventor
Friedrich Scheiflinger
Randolf Kerschbaumer
Manfred Rieger
Michael Thiele
C Geert Mudde
Juergen Muellberg
Rene Hoet
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX2010007406A publication Critical patent/MX2010007406A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales y porciones de unión a antígeno de los mismos que específicamente se unen a la C-terminal o la región central del factor inhibidor de migración de macrófago (MIF). Estos anticuerpos anti-MIF y porciones de unión a antígeno de los mismos además inhiben la función biológica de MIF. La solicitud también se refiere a inmunoglobulinas de cadena pesada y ligera aisladas derivadas de los anticuerpos anti-MIF y moléculas de ácido nucleico que codifican dichas inmunoglobulinas. La presente solicitud también se refiere a un método para identificar anticuerpos anti-MIF, composiciones farmacéuticas que comprenden estos anticuerpos y un método para utilizar estos anticuerpos y composiciones para el tratamiento de condiciones relacionadas con el MIF.
MX2010007406A 2008-01-04 2008-12-30 Anticuerpos anti-factor inhibidor de migracion de macrofago (mif). MX2010007406A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1898808P 2008-01-04 2008-01-04
US9468508P 2008-09-05 2008-09-05
PCT/EP2008/011146 WO2009086920A1 (en) 2008-01-04 2008-12-30 Anti mif antibodies

Publications (1)

Publication Number Publication Date
MX2010007406A true MX2010007406A (es) 2010-10-05

Family

ID=40535633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007406A MX2010007406A (es) 2008-01-04 2008-12-30 Anticuerpos anti-factor inhibidor de migracion de macrofago (mif).

Country Status (23)

Country Link
US (3) US20090220521A1 (es)
EP (4) EP2754671B1 (es)
JP (1) JP5502752B2 (es)
KR (2) KR20160105943A (es)
CN (2) CN103724430B (es)
AU (1) AU2008346517B2 (es)
BR (1) BRPI0821682A2 (es)
CA (1) CA2711029A1 (es)
CY (1) CY1117302T1 (es)
DK (1) DK2231707T3 (es)
ES (3) ES2791333T3 (es)
HK (1) HK1147762A1 (es)
HR (1) HRP20150224T1 (es)
IL (1) IL206715A (es)
MX (1) MX2010007406A (es)
NZ (3) NZ586600A (es)
PL (2) PL2231707T3 (es)
PT (1) PT2231707E (es)
RS (1) RS53906B1 (es)
RU (2) RU2509777C2 (es)
SI (1) SI2231707T1 (es)
WO (1) WO2009086920A1 (es)
ZA (1) ZA201004973B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008346517B2 (en) * 2008-01-04 2013-12-05 Baxalta GmbH Anti MIF antibodies
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
AU2012320597C1 (en) * 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
WO2013050457A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Characterization of cho-mif gene and protein, and use thereof
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
CN105452867A (zh) * 2012-07-10 2016-03-30 巴克斯特保健股份有限公司 抗-mif的免疫组织化学
JP2016502669A (ja) * 2012-12-07 2016-01-28 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 抗ｍｉｆ抗体細胞遊走アッセイ
US10613100B2 (en) * 2014-01-03 2020-04-07 Baxalta Incorporated Anti-MIF immunohistochemistry
EP3183581A1 (en) 2014-08-22 2017-06-28 Baxalta GmbH Detection of cho-mif contaminations
WO2016156489A1 (en) 2015-03-31 2016-10-06 Baxalta GmbH Dosage regimen for anti-mif antibodies
US20180155419A1 (en) 2015-05-18 2018-06-07 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CN109868311B (zh) * 2017-12-01 2023-10-20 上海市精神卫生中心 Mif及其预测二代抗精神病药物诱导的代谢不良反应的应用
KR20210018800A (ko) * 2018-06-07 2021-02-18 온코원 리서치 앤드 디벨롭먼트 게엠베하 암 치료를 위한 항-oxMIF/항-CD3 항체
EP3757252B1 (en) 2019-06-28 2022-03-30 Walter Ag A coated cutting tool
AU2020397229A1 (en) 2019-12-06 2022-06-30 Oncoone Research & Development Gmbh Anti-oxMIF/anti-CD3 bispecific antibody constructs
EP4222170B1 (en) 2020-10-02 2024-03-20 OncoOne Research & Development GmbH Improved anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity
EP4288118A1 (en) 2021-02-03 2023-12-13 OncoOne Research & Development GmbH Anti-oxmif radioimmunoconjugate
WO2023031397A1 (en) 2021-09-03 2023-03-09 Oncoone Research & Development Gmbh IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY
WO2023133360A2 (en) * 2022-01-10 2023-07-13 Phenomic Ai Anti-collagen triple helix repeat containing 1 (cthrc1) antibodies and methods of using the same
CN114573693A (zh) * 2022-04-25 2022-06-03 中国人民解放军陆军军医大学 一种听觉发育中免疫调节分子mif抗体制备方法
CN115814069B (zh) * 2022-10-31 2023-07-21 四川大学华西医院 Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
JPH0977799A (ja) * 1995-09-13 1997-03-25 Sapporo Immuno Diagnostic Lab:Kk ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
PT1156823E (pt) * 1999-02-12 2009-01-08 Scripps Research Inst Métodos para tratamento de tumores e metástases utilizando uma combinação de terapias anti-angiogénicas e imunitárias
US20030235584A1 (en) 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
AU2008346517B2 (en) * 2008-01-04 2013-12-05 Baxalta GmbH Anti MIF antibodies

Also Published As

Publication number Publication date
EP3118223B8 (en) 2020-04-15
IL206715A (en) 2015-06-30
US20090220521A1 (en) 2009-09-03
BRPI0821682A2 (pt) 2015-06-16
EP2231707A1 (en) 2010-09-29
EP2754671B1 (en) 2016-12-21
EP2231707B1 (en) 2014-12-24
WO2009086920A1 (en) 2009-07-16
EP2754671A2 (en) 2014-07-16
SI2231707T1 (sl) 2015-04-30
NZ586600A (en) 2012-05-25
PL2231707T3 (pl) 2015-05-29
US8668909B2 (en) 2014-03-11
US20100260768A1 (en) 2010-10-14
EP3118223A1 (en) 2017-01-18
EP2754671A3 (en) 2015-07-08
ZA201004973B (en) 2011-03-30
IL206715A0 (en) 2010-12-30
ES2623653T3 (es) 2017-07-11
CY1117302T1 (el) 2017-04-26
NZ611117A (en) 2014-10-31
HRP20150224T1 (en) 2015-06-05
ES2531629T3 (es) 2015-03-18
EP2548890A1 (en) 2013-01-23
CN103724430A (zh) 2014-04-16
AU2008346517A1 (en) 2009-07-16
ES2791333T3 (es) 2020-11-03
RU2509777C2 (ru) 2014-03-20
NZ596409A (en) 2013-05-31
KR20100102197A (ko) 2010-09-20
PL3118223T3 (pl) 2021-04-06
PT2231707E (pt) 2015-03-25
JP2011510616A (ja) 2011-04-07
DK2231707T3 (en) 2015-03-02
JP5502752B2 (ja) 2014-05-28
US20150023978A1 (en) 2015-01-22
RU2010132647A (ru) 2012-02-10
RS53906B1 (en) 2015-08-31
CN103724430B (zh) 2016-09-21
CA2711029A1 (en) 2009-07-16
KR101654678B1 (ko) 2016-09-08
AU2008346517B2 (en) 2013-12-05
CN101983207B (zh) 2016-01-20
HK1147762A1 (en) 2011-08-19
RU2013153592A (ru) 2015-06-10
CN101983207A (zh) 2011-03-02
EP3118223B1 (en) 2020-02-19
KR20160105943A (ko) 2016-09-07

Similar Documents

Publication Publication Date Title
MX2010007406A (es) Anticuerpos anti-factor inhibidor de migracion de macrofago (mif).
MX2009006891A (es) Anticuerpos cd44.
MY160892A (en) Antibodies to ccr2
EP2511301A3 (en) Human antibodies to ERBB2
PH12014501872A1 (en) P-cadherin antibodies
TNSN07394A1 (en) Antibodies to myostatin
WO2008060331A3 (en) Antibodies to sars coronavirus
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
WO2008030611A3 (en) Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
MX2019015195A (es) Anticuerpos contra madcam.
BR112012007365A2 (pt) proteínas de ligação à il-1
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
UA109633C2 (uk) Антитіло людини проти тканинного фактора
NO20090224L (no) Anti-IL-6 monoklonale antistoffer og anvendelser derav
NO20083697L (no) Fremgangsmater for anvendelse av antistoffer mot human IL-22
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
EA202091747A1 (ru) Составы антитела b7-h4
MX2014005570A (es) El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
UA84539C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека
UA102085C2 (ru) ВЫДЕЛЕННОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С hGM-CSF, И КОМПОЗИЦИЯ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ

Legal Events

Date Code Title Description
FG Grant or registration